• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Natural killer cells are required for the recruitment of CD8+ T cells and the efficacy of immune checkpoint blockade in melanoma brain metastases

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    e009522.full.pdf
    Size:
    5.326Mb
    Format:
    PDF
    Description:
    Found with Open Access Button
    Download
    Authors
    Fife, Christopher
    Williams, J.
    James, F.
    Gregory, S.
    Andreou, T.
    Sunderland, A.
    McKimmie, C.
    Brownlie, R. J.
    Salmond, R. J.
    Heaton, S.
    Errington-Mais, F.
    Hadi, Z.
    Westhead, D. R.
    Hall, M.
    Davie, A.
    Emmett, A.
    Lorger, M.
    Show allShow less
    Affiliation
    Cancer Research UK National Biomarker Centre, The University of Manchester, Manchester, UK.
    Issue Date
    2024
    
    Metadata
    Show full item record
    Abstract
    Background Brain metastases (BrM) affect up to 60% of patients with metastatic melanoma and are associated with poor prognosis. While combined immune checkpoint blockade of programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) demonstrates intracranial efficacy in a proportion of patients with melanoma, the responses are rarely durable, particularly in patients with symptomatic BrM. The brain is an immune-specialized organ and immune responses are regulated differently to the periphery.Methods Using our previously established two-site model of melanoma BrM with concomitant intracranial and extracranial tumors, in which clinically observed efficacy of the combined PD-1/CTLA-4 (PC) blockade can be reproduced, we here explored the role of natural killer (NK) cells in BrM, using functional studies, immunophenotyping and molecular profiling.Results We demonstrate that NK cells are required for the intracranial efficacy of PC blockade. While both perforin and interferon gamma were necessary for the PC blockade-dependent control of intracranial tumor growth, NK cells isolated from intracranial tumors demonstrated only a limited cancer cell killing ability, and PC blockade did not alter the abundance of NK cells within tumors. However, the depletion of NK cells in PC blockade-treated mice led to tumor molecular profiles reminiscent of those observed in intracranial tumors that failed to respond to therapy. Furthermore, the depletion of NK cells resulted in a strikingly reduced abundance of CD8+ T cells within intracranial tumors, while the abundance of other immune cell populations including CD4+ T cells, macrophages and microglia remained unaltered. Adoptive T cell transfer experiments demonstrated that PC blockade-induced trafficking of CD8+ T cells to intracranial tumors was chemokine-dependent. In line with this, PC blockade enhanced intratumoral expression of several T cell-attracting chemokines and we observed high expression levels of cognate chemokine receptors on BrM-infiltrating CD8+ T cells in mice, as well as in human BrM. Importantly, the depletion of NK cells strikingly reduced the intratumoral expression levels of T cell attracting chemokines and vascular T cell entry receptors that were upregulated following PC blockade.Conclusion Our data demonstrate that NK cells underpin the efficacy of PC blockade in BrM by orchestrating the 'responder' molecular profile in tumors, and by controlling the intratumoral abundance of CD8+ T cells through regulation of multiple key molecular mediators of T cell trafficking.
    Citation
    Fife C, Williams J, James F, Gregory S, Andreou T, Sunderland A, et al. Natural killer cells are required for the recruitment of CD8+ T cells and the efficacy of immune checkpoint blockade in melanoma brain metastases. Journal for immunotherapy of cancer. 2024 Nov 17;12(11). PubMed PMID: 39551601. Pubmed Central PMCID: PMC11574513. Epub 2024/11/18. eng.
    Journal
    Journal for immunotherapy of cancer
    URI
    http://hdl.handle.net/10541/627332
    DOI
    10.1136/jitc-2024-009522
    PubMed ID
    39551601
    Additional Links
    https://dx.doi.org/10.1136/jitc-2024-009522
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1136/jitc-2024-009522
    Scopus Count
    Collections
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8(+) T cell trafficking.
    • Authors: Taggart D, Andreou T, Scott KJ, Williams J, Rippaus N, Brownlie RJ, Ilett EJ, Salmond RJ, Melcher A, Lorger M
    • Issue date: 2018 Feb 13
    • NK cells link immune-checkpoint blockade immunotherapy and response in melanoma brain metastases.
    • Authors: Kohanbash G, Frederico SC, Raphael I
    • Issue date: 2025 Mar 18
    • Targeting the atypical chemokine receptor 2 (Ackr2) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model.
    • Authors: Noman MZ, Szpakowska M, Xiao M, Gao R, Van Moer K, Kumar A, Ollert M, Berchem G, Chevigné A, Janji B
    • Issue date: 2025 Dec
    • Combination of NKG2A and PD-1 Blockade Improves Radiotherapy Response in Radioresistant Tumors.
    • Authors: Battaglia NG, Murphy JD, Uccello TP, Hughson A, Gavras NW, Caldon JJ, Gerber SA, Lord EM
    • Issue date: 2022 Aug 1
    • Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
    • Authors: Olivo Pimentel V, Marcus D, van der Wiel AM, Lieuwes NG, Biemans R, Lieverse RI, Neri D, Theys J, Yaromina A, Dubois LJ, Lambin P
    • Issue date: 2021 Mar
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.